This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
EyePoint, Inc.
Q12025
5/7/2025
Tawanda
Conference Operator
Good morning. My name is Tawanda, and I'll be your conference operator today. At this time, I would like to welcome everyone to the IFORN First Quarter 2025 Financial Results and Recent Corporate Development Conference Call. There will be a question and answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to George Elston, Executive Vice President, and Chief Financial Officer of Affluent. Sir, you may begin.
Dr. Jay Duker
President and Chief Executive Officer of iPoint
Thank you, and thank you all for joining us on today's conference call to discuss iPoint's first quarter 2025 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer of iPoint. Jay will begin with a review of recent corporate updates and discuss the ongoing clinical trials for review. I will close with commentary on the first quarter 2025 financial results, and we will then open the call for your questions.
George Elston
Executive Vice President and Chief Financial Officer of iPoint
Earlier this morning, we issued a press release detailing our financial results and recent corporate developments. A copy of the release can be found in the Investor Relations tab on the company website, www.ipointpharma.com.
You're reading a preview of the EYPT Q1 2025 earnings call.
Free account.
Disclaimer